Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy
Background: Oxaliplatin, combined with capecitabine (CAPOX) or infused 5-fluorouracil (FOLFOX), is standard of care in the adjuvant treatment of colorectal cancer (CRC). Prospective data on prevalence of oxaliplatin induced acute and long-term neuropathy in a real-life patient population and its eff...
Main Authors: | , , , , , |
---|---|
Format: | Dataset |
Language: | unknown |
Published: |
Taylor & Francis
2019
|
Subjects: | |
Online Access: | https://dx.doi.org/10.6084/m9.figshare.7583348 https://tandf.figshare.com/articles/Long-term_neuropathy_and_quality_of_life_in_colorectal_cancer_patients_treated_with_oxaliplatin_containing_adjuvant_chemotherapy/7583348 |
id |
ftdatacite:10.6084/m9.figshare.7583348 |
---|---|
record_format |
openpolar |
spelling |
ftdatacite:10.6084/m9.figshare.7583348 2023-05-15T18:28:33+02:00 Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy L. M. Soveri A. Lamminmäki U. A. Hänninen M. Karhunen P. Bono P. Osterlund 2019 https://dx.doi.org/10.6084/m9.figshare.7583348 https://tandf.figshare.com/articles/Long-term_neuropathy_and_quality_of_life_in_colorectal_cancer_patients_treated_with_oxaliplatin_containing_adjuvant_chemotherapy/7583348 unknown Taylor & Francis https://dx.doi.org/10.1080/0284186x.2018.1556804 Creative Commons Attribution 4.0 International https://creativecommons.org/licenses/by/4.0/legalcode cc-by-4.0 CC-BY Medicine Neuroscience Biotechnology Ecology FOS Biological sciences Immunology FOS Clinical medicine 69999 Biological Sciences not elsewhere classified Cancer Science Policy dataset Dataset 2019 ftdatacite https://doi.org/10.6084/m9.figshare.7583348 https://doi.org/10.1080/0284186x.2018.1556804 2021-11-05T12:55:41Z Background: Oxaliplatin, combined with capecitabine (CAPOX) or infused 5-fluorouracil (FOLFOX), is standard of care in the adjuvant treatment of colorectal cancer (CRC). Prospective data on prevalence of oxaliplatin induced acute and long-term neuropathy in a real-life patient population and its effects on quality of life (QOL) and survival is limited, and scarce in CAPOX versus FOLFOX treated, especially in a subarctic climate. Methods: One hundred forty-four adjuvant CRC patients (all 72 CAPOX cases and 72 matched FOLFOX controls) were analyzed regarding oxaliplatin induced sensory neuropathy, which was graded according to NCI-CTCAEv3.0. Ninety-two long-term survivors responded to the QOL (EORTC QLQ-C30) and Chemotherapy-Induced Peripheral Neuropathy (EORTC CIPN20) questionnaires and were interviewed regarding long-term neuropathy. Results: Acute neurotoxicity was present in 94% (136/144) during adjuvant therapy and there was a significant association between acute neurotoxicity and long-term neuropathy ( p p = .031), decreased role functioning ( p = .040), and more diarrhea ( p = .021) in QLQ-C30 items. There were no differences in acute neurotoxicity, long-term neuropathy, or in QOL between CAPOX and FOLFOX treated. Neuropathy showed no pattern of variation according to starting and stopping month or treatment during winter. Conclusions: Neuropathy following oxaliplatin containing adjuvant chemotherapy is present in two-thirds, years after cessation, and impairs some QOL scales. There is no difference in severity of acute or long-term neuropathy between CAPOX and FOLFOX treated and QOL is similar. No seasonal variation in neuropathy was noted. Dataset Subarctic DataCite Metadata Store (German National Library of Science and Technology) |
institution |
Open Polar |
collection |
DataCite Metadata Store (German National Library of Science and Technology) |
op_collection_id |
ftdatacite |
language |
unknown |
topic |
Medicine Neuroscience Biotechnology Ecology FOS Biological sciences Immunology FOS Clinical medicine 69999 Biological Sciences not elsewhere classified Cancer Science Policy |
spellingShingle |
Medicine Neuroscience Biotechnology Ecology FOS Biological sciences Immunology FOS Clinical medicine 69999 Biological Sciences not elsewhere classified Cancer Science Policy L. M. Soveri A. Lamminmäki U. A. Hänninen M. Karhunen P. Bono P. Osterlund Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy |
topic_facet |
Medicine Neuroscience Biotechnology Ecology FOS Biological sciences Immunology FOS Clinical medicine 69999 Biological Sciences not elsewhere classified Cancer Science Policy |
description |
Background: Oxaliplatin, combined with capecitabine (CAPOX) or infused 5-fluorouracil (FOLFOX), is standard of care in the adjuvant treatment of colorectal cancer (CRC). Prospective data on prevalence of oxaliplatin induced acute and long-term neuropathy in a real-life patient population and its effects on quality of life (QOL) and survival is limited, and scarce in CAPOX versus FOLFOX treated, especially in a subarctic climate. Methods: One hundred forty-four adjuvant CRC patients (all 72 CAPOX cases and 72 matched FOLFOX controls) were analyzed regarding oxaliplatin induced sensory neuropathy, which was graded according to NCI-CTCAEv3.0. Ninety-two long-term survivors responded to the QOL (EORTC QLQ-C30) and Chemotherapy-Induced Peripheral Neuropathy (EORTC CIPN20) questionnaires and were interviewed regarding long-term neuropathy. Results: Acute neurotoxicity was present in 94% (136/144) during adjuvant therapy and there was a significant association between acute neurotoxicity and long-term neuropathy ( p p = .031), decreased role functioning ( p = .040), and more diarrhea ( p = .021) in QLQ-C30 items. There were no differences in acute neurotoxicity, long-term neuropathy, or in QOL between CAPOX and FOLFOX treated. Neuropathy showed no pattern of variation according to starting and stopping month or treatment during winter. Conclusions: Neuropathy following oxaliplatin containing adjuvant chemotherapy is present in two-thirds, years after cessation, and impairs some QOL scales. There is no difference in severity of acute or long-term neuropathy between CAPOX and FOLFOX treated and QOL is similar. No seasonal variation in neuropathy was noted. |
format |
Dataset |
author |
L. M. Soveri A. Lamminmäki U. A. Hänninen M. Karhunen P. Bono P. Osterlund |
author_facet |
L. M. Soveri A. Lamminmäki U. A. Hänninen M. Karhunen P. Bono P. Osterlund |
author_sort |
L. M. Soveri |
title |
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy |
title_short |
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy |
title_full |
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy |
title_fullStr |
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy |
title_full_unstemmed |
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy |
title_sort |
long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy |
publisher |
Taylor & Francis |
publishDate |
2019 |
url |
https://dx.doi.org/10.6084/m9.figshare.7583348 https://tandf.figshare.com/articles/Long-term_neuropathy_and_quality_of_life_in_colorectal_cancer_patients_treated_with_oxaliplatin_containing_adjuvant_chemotherapy/7583348 |
genre |
Subarctic |
genre_facet |
Subarctic |
op_relation |
https://dx.doi.org/10.1080/0284186x.2018.1556804 |
op_rights |
Creative Commons Attribution 4.0 International https://creativecommons.org/licenses/by/4.0/legalcode cc-by-4.0 |
op_rightsnorm |
CC-BY |
op_doi |
https://doi.org/10.6084/m9.figshare.7583348 https://doi.org/10.1080/0284186x.2018.1556804 |
_version_ |
1766211077914230784 |